Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n
As Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted the lid on yet another trial failure involving two drugs aimed at this
It’s not far off crunch time for Roche’s potential spinal muscular atrophy (SMA) drug, risdiplam, which the big Swiss pharma hopes will generate blockbuster revenues as well as taking marke
Roche has seen its pharmaceutical sales increase in 2019 as it fought off the impact of cheaper near-copies of its most successful drugs with a batch of new medicines.
